Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00346151 · ClinicalTrials.gov registry record · Phase 2
Belatacept to Prevent Organ Rejection in Kidney Transplant Patients
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT00346151 is a Phase 2 study that was terminated before completion, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 5 participants.
The verdict
NCT00346151, a Phase 2 study, was terminated before completion, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
Belatacept is an experimental medication shown in clinical trials to have immune system suppression properties in people who have had renal (e.g., kidney) transplants. This study will determine whether a combination of anti-rejection drugs, including belatacept, can prevent the rejection of a first-time, non-human leukocyte antigen (HLA) identical renal transplant and allow patients to be safely withdrawn from anti-rejection therapy one year post-transplant.
Interventions
- DRUG Sirolimus
- DRUG Belatacept
- DRUG methylprednisolone
- DRUG Anti-thymocyte globulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2006-12 |
| Est. Completion | 2010-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00346151
The ClinicalTrials.gov registry entry for NCT00346151 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Sirolimus is the first listed.
NCT00346151 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00346151 about?
NCT00346151 is a clinical study titled "Belatacept to Prevent Organ Rejection in Kidney Transplant Patients". Belatacept is an experimental medication shown in clinical trials to have immune system suppression properties in people who have had renal (e.g., kidney) transplants. This study will determine whether a combination of anti-rejection drugs, including belatacept, can prevent the rejection of a first-...
What is the current status of trial NCT00346151?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2006-12. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00346151?
The interventions under investigation include: Sirolimus (DRUG), Belatacept (DRUG), methylprednisolone (DRUG), Anti-thymocyte globulin (DRUG).
Who is sponsoring clinical trial NCT00346151?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.